This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Translate Bio, Inc.
Translate Bio, Inc., a pioneering biotechnology firm based in the United States, focuses on the development of mRNA therapeutics. Founded in 2016, the company has rapidly advanced its position within the biopharmaceutical industry, particularly in the areas of genetic medicine and vaccine development. With its headquarters in Lexington, Massachusetts, Translate Bio has made significant strides in harnessing the potential of messenger RNA to create innovative treatments for various diseases. The company's core offerings include mRNA-based therapeutics designed to address unmet medical needs, setting it apart through its unique approach to drug development. Recognised for its contributions to the field, Translate Bio has established itself as a key player in the biotechnology landscape, particularly in the context of rapid advancements in mRNA technology.
DitchCarbon Score
How does Translate Bio, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Translate Bio, Inc.'s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Translate Bio, Inc., headquartered in the US, currently does not have specific carbon emissions data available for recent years. The company is a current subsidiary of Sanofi, and as such, it inherits emissions data and climate commitments from its parent organisation. Translate Bio, Inc. is aligned with Sanofi's climate initiatives, which include participation in the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, all at a cascade level of 1. However, specific reduction targets or achievements for Translate Bio, Inc. have not been disclosed. As part of its commitment to sustainability, Translate Bio, Inc. is expected to adhere to the broader climate strategies set forth by Sanofi, which may include significant reduction targets and initiatives aimed at minimising carbon emissions across various scopes. However, without specific data or targets available, the details of these commitments remain vague.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2010 | 2011 | 2012 | 2013 | 2015 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 545,114,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 677,549,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | 0,000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Translate Bio, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
